Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.46 USD

28.46
3,502,953

-0.06 (-0.21%)

Updated Oct 31, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.

Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase?

by Zacks Equity Research

In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN

by Kinjel Shah

Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $36.71, moving +1.27% from the previous trading session.

Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

by Zacks Equity Research

Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

What's in the Cards for Pfizer (PFE) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.

Sweta Killa headshot

Healthcare ETFs Looks Strong Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.

Myovant Eyes Relugolix Approval for Advanced Prostate Cancer

by Zacks Equity Research

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

by Sweta Killa

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Novartis To Initiate Hydroxychloroquine Study for Coronavirus

by Zacks Equity Research

Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.

Sanghamitra Saha headshot

5 Best Leveraged ETF Areas of Last Week

by Sanghamitra Saha

If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts

by Kinjel Shah

J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines

Sanghamitra Saha headshot

Optimism Back in Wall Street? ETFs Areas to Win the Most

by Sanghamitra Saha

Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.

Pfizer (PFE) Stock Moves -1.26%: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $35.98, marking a -1.26% move from the previous day.

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

Ekta Bagri headshot

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

by Ekta Bagri

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Pfizer (PFE) Progressing Well With its Coronavirus Program

by Zacks Equity Research

Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.

Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak

by Zacks Equity Research

Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.

Mark Vickery headshot

Top Analyst Reports for Alibaba, Pfizer & S&P Global

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).

Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer

by Zacks Equity Research

Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.

J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.

    Merck's Keytruda Gets FDA's Priority Review for Solid Tumors

    by Zacks Equity Research

    Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

    Kinjel Shah headshot

    Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

    by Kinjel Shah

    The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.